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Systemic
vasculitides

Part 2: Small vessel
diseases
SEAN M. CONTE

BA, MB BS;

PETER R. VALE

MB BS, FRACP, FCSANZ, FACC, FACP

Small vessel vasculitides often manifest as
neurological, renal, pulmonary and dermatological
symptoms. Clinical features of systemic vasculitides
are often nonspecific; therefore, it is important that
GPs be aware of the range of symptoms that can
help in the differential diagnosis, treatment and
management of this diverse group of conditions.

P

art one of this two-part series on systemic vasculitides
covered the large, medium and variable vessel vasculitides. We saw that most primary vasculitides are
typified by nonspecific systemic manifestations such as
fever, weight loss and lethargy but that classic presentations often
aid our diagnostic efforts. We also stressed the importance of
identifying high-mortality and high-morbidity situations such
as visual impairment in giant cell arteritis (GCA) and coronary
artery aneurysms in Kawasaki disease.
Part two will discuss small vessel diseases, a diverse group
of diseases often with neurological, renal, pulmonary and
dermatological manifestations, which are summarised in Table 1.
We will conclude with a summary outlining a general approach

KEY POINTS
• The two main categories of small vessel vasculitis are
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antineutrophil cytoplasmic antibody-associated and
immune complex-associated disease, best diagnosed
with renal and/or pulmonary biopsy.
Severe renal failure and pulmonary haemorrhage are
high-risk features that require urgent management.
Eosinophilic granulomatosis with polyangiitis can be
associated with severe cardiac disease including heart
failure, conduction abnormalities and pericarditis.
These complications account for half of the mortality
associated with this disease.
Hypocomplementaemic urticarial vasculitis and
cryoglobulinaemic vasculitis are commonly associated
with underlying systemic conditions including
inflammatory rheumatological disease, chronic viral
hepatitis and haematological malignancies. These
should be screened for at the time of diagnosis.
Leukocytoclastic vasculitis is the most common
vasculitis encountered in clinical practice, only involves
the skin and is most commonly associated with
medication use.
Patients receiving long-term corticosteroid or immuno
suppressive therapy require dedicated screening for
chronic iatrogenic complications such as diabetes
mellitus, osteoporosis, hypertension, obesity,
opportunistic infections and secondary malignancies.
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Systemic vasculitides Part 2 continued

TABLE 1. SUMMARY OF CLINICAL FEATURES AND ASSESSMENT OF SMALL VESICLE DISEASE VASCULITIDES
Disease entity

Clinical patient features

Investigations and diagnosis

Management options

Granulomatosis with
polyangiitis (GPA) /
microscopic
polyangiitis (MPA)

• Sinusitis
• Haemoptysis
• Haematuria

• Cytoplasmic antineutrophil
cytoplasmic antibodies: protease
3 (granulomatosis with
polyangiitis), myeloperoxidase
(MPA)

• Induction: corticosteroids +
cyclophosphamide or rituximab
• Maintenance: azathioprine,
methotrexate, rituximab (GPA)

Eosinophilic
granulomatosis with
polyangiitis

• Asthma, atopy
• Mononeuritis multiplex
• Cardiac conduction
abnormalities

•
•
•
•

• Induction: corticosteroids +/−
cyclophosphamide
• Maintenance: azathioprine,
methotrexate, leflunomide
• Anti-interleukin-5 monoclonal
antibody

Anti-glomerular
basement membrane
disease

• Haemoptysis
• Haematuria
• Acute renal failure

• p-ANCA
• Myeloperoxidase
• Antibodies against type IV
collagen on ELISA, western blot,
and immunofluorescence of renal
or pulmonary biopsy

• Critical/Emergent: intubation,
dialysis
• Initial: plasmapheresis +
corticosteroid +
cyclophosphamide
• Alternate: rituximab or
mycophenolate
• Maintenance: low-dose
prednisolone +/− second agent

IgA-related vasculitis

• Asian populations
• Palpable purpura on lower
limbs and buttocks
• Migratory oligoarthralgia
• Abdominal pain
• IgA nephropathy

•
•
•
•

Renal function
Urine sediment
Urine protein
Immunofluorescence of biopsy
specimen (IgA)

• Uncomplicated: NSAIDs, rest,
hydration
• Proteinuria: ACE inhibitor or ARB
• Prolonged: low-dose prednisolone
• Severe or marked renal
dysfunction: mycophenolate +/−
cyclophosphamide

Hypocomplementaemic
urticarial vasculitis

• Constitutional symptoms
• Chronic obstructive
pulmonary disease
• Mild renal dysfunction
• Migratory polyarthritis
• Associations: SLE, Sjögren’s
disease, drugs, HCV and
HBV, complement deficiency,
haematological malignancies

• Low C3 and C4
• Leukocytoclastic vasculitis on
biopsy
• Renal function and urinalysis
• Hepatitis serology
• ANCA, antinuclear antibody,
extractable nuclear antigens, etc.
• Serum protein electrophoresis
and immunofixation

• Mild: NSAIDs and antihistamines
• Moderate: prednisolone +
colchicine, dapsone,
hydroxychloroquine
• Severe: mycophenolate

Cryoglobulinaemic
vasculitis

• Cutaneous manifestations
• Arthralgias (hands, knees,
ankles)
• Peripheral neuropathy
• Glomerulonephritis

• Screening for connective tissue
diseases (SLE, Sjögren’s)
• Screening for haematological
malignancy (multiple myeloma,
Waldenström’s)
• Evaluation of renal function and
proteinuria
• Renal biopsy

•
•
•
•

Leukocytoclastic
vasculitis

• Temporal relationship to new
or changed medication
• Palpable purpura
• Maculopapular rash

• Absence of evidence of major
visceral involvement
• Exclusion of systemic vasculitis
or infection
• Perivascular neutrophils
• Fibrinoid necrosis

• Supportive care
• Cessation of offending
medication

p-ANCA
Eosinophilia
Chest imaging (patchy opacities)
Surgical lung biopsy

Mild: NSAIDs, rest hydration
Proteinuria: ACE inhibitor or ARB
Moderate: low-dose prednisolone
Severe/prolonged:
cyclophosphamide +/−
mycophenolate

Abbreviations: ARB = angiotensin-receptor blocker; c-ANCA = cytoplasmic antineutrophil cytoplasmic antibodies; ELISA = enzyme-linked immunosorbent assay;
HBV = hepatitis B virus; HCV = hepatitis C virus; IgA = immunoglobin A; p-ANCA = peripheral antineutrophil cytoplasmic antibodies; SLE = systemic lupus erythematosus.
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to investigating and managing systemic
vasculitides.

Classification and clinical
features
Antineutrophil cytoplasmic
antibody-associated vasculitis
Granulomatosis with polyangiitis and
microscopic polyangiitis
Granulomatosis with polyangiitis (GPA),
formerly known as Wegener’s disease,
and microscopic polyangiitis (MPA) most
commonly occur in patients over the age
of 65 years and more often in Caucasian
populations, affecting men and women
equally. GPA affects the respiratory and
glomerular epithelia producing haemoptysis and haematuria, respectively. Ear,
nose and throat (ENT) manifestations
such as sinusitis, otitis media, ulcers,
polychondritis and subglottic stenosis
are also classically seen. Dermatologic
and ophthalmologic involvement can
occur with variable frequency. Cytoplasmic antineutrophil cytoplasmic anti
bodies (c-ANCA) are seen in over 80%
of patients with GPA and MPA and are
typically associated with protease 3 in
GPA and myeloperoxidase (MPO) in
MPA.1 Urinalysis discloses haemoglobin
and red-cell casts indicating glomerular
inflammation. CT of the head, sinuses
and chest is recommended in cases with
ENT manifestations and pulmonary
disease to clarify the site and severity of
disease and guide biopsy ( Figure 1).2 GPA
and MPA are best diagnosed and differentiated on biopsy, usually renal or pulmonary, and defined by the presence of
granulomatous inflammation.
The goals of therapy are to reduce the
incidence of renal failure and haemoptysis,
and induce remission. Initial therapy
begins with corticosteroids in combination with cyclophosphamide, rituximab
or methotrexate for mild nonorganthreatening disease. Plasma exchange therapy should be added in three situations:
1. when patients have rapidly progressive
renal impairment or renal failure at
the point of requiring dialysis

2. in those with pulmonary
haemorrhage
3. in the presence of concomitant 
anti-glomerular basement
membrane antibodies.3
Maintenance therapy is started once
corticosteroids are tapered, usually after
three to six months, and preferred agents
are azathioprine or methotrexate. Rituximab is an alternative agent for maintenance
therapy but is not recommended for MPOANCA positive disease.4

Figure 1. CT of the chest in a patient with
granulomatosis with polyangiitis.
Case courtesy of Radswiki, Radiopaedia.org, rID: 12079.

Eosinophilic granulomatosis with
polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as
Churg-Strauss syndrome, is a multisystem
vasculitis of the small and medium-sized
vessel with gradual onset in the second or
third decade of life. EGPA is typified by
chronic rhinosinusitis, asthma and atopy
in the context of peripheral eosinophilia.
Atopic and eosinophilic phases of the
illness generally predate nonspecific signs
of systemic vasculitis such as fevers, weight
loss and lassitude by as much as a decade.
Cardiac involvement in the form of heart
failure, conduction abnormalities or
pericarditis accounts for roughly half of
the mortality associated with EGPA. Mononeuritis multiplex is a classic neurological
manifestation of EGPA and may be a clue
to differentiate the disease from simple
asthma or sinusitis in its early phase. Renal
involvement is present in most patients
with variable histopathology. Finally, it is
worth noting that patients with EGPA are
at a significantly increased risk of venous
thromboembolism compared with the
general population.5 Patients with EGPA
have a raised peripheral eosinophil count,
usually above 1500 mcmol/L, and roughly
half have a positive peripheral antineutrophil cytoplasmic antibodies (p-ANCA).
A case study on the diagnosis of EGPA is
outlined in the Box.
Chest imaging, especially CT, typically
demonstrates transient patchy opacities,
peribronchial and septal thickening, and
helps guide bronchoalveolar lavage and

pulmonary biopsy. Surgical lung biopsy
revealing extravascular granulomas with
eosinophilic pneumonia is the gold standard diagnostic test for EGPA and is superior
in demonstrating typical histopathology
to a transbronchial approach.6 Spirometry
and pulmonary function testing typically
demonstrate obstruction, w
 ith asthmatic-range reversibility with decreased lung
volumes and impairment of gas transfer.
Electrocardiography, echocardiography
and occasionally endomyocardial biopsy
are prognostically useful tests for determining the extent of organ involvement
and guiding therapy.7
Initially, treatment with corticosteroids
achieves remission without the use of
adjuvant therapy in the majority of patients
with EGPA. Cyclophosphamide is added
when severe multiorgan involvement is
present. Maintenance therapy with
azathioprine, methotrexate or leflunomide
is reserved for severe disease without
multiorgan involvement and is continued
for 12 to 18 months.8 Anti-interleukin-5
monoclonal antibody therapy (mepolizumab and reslizumab) has shown promise
in treating EGPA.9
Immune complex-associated
vasculitis
Anti-glomerular basement membrane
disease
Anti-glomerular basement membrane
(GBM) disease, also known as Good
pasture’s disease, is a small vessel vasculitis
characterised by the presence of anti-GBM
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CASE STUDY. SMALL VESSEL DISEASE VASCULITIS
A 39-year-old woman with a history of asthma presents with a 3-month history of
progressive exertional dyspnoea and cough. She has noticed relief from two courses
of oral corticosteroids prescribed by her general practitioner for asthma exacerbation
management but worsens when she ceases these after one week. On examination, a
prolonged expiratory phase, mild diffuse wheeze and a mild left-sided foot drop is
noted. Laboratory investigations reveal a serum creatinine level of 120 mcg/dL,
peripheral eosinophil count of 2350 mcmol/L and a positive peripheral antineutrophil
cytoplasmic antibody test. CT of the chest is remarkable for multilobar patchy
opacities and septal thickening. Sputum microbiology, serum Aspergillus precipitins
and skin prick testing are negative.
What diagnosis is most likely?
The constellation of asthma, renal impairment, eosinophilia and peripheral neuropathy
is highly suggestive of eosinophilic granulomatosis with polyangiitis.
What other investigations should be undertaken?
This patient requires an electrocardiogram and potentially an echocardiogram to
evaluate for cardiac involvement as this is responsible for up to half the mortality in
this disease. Pulmonary function testing and imaging is prudent and can guide surgical
biopsy if diagnosis is uncertain as this is the gold standard diagnostic test.
How should the patient be managed initially?
Corticosteroids are the best initial therapy and, if severe, can be combined with
cyclophosphamide to induce remission.

antibodies, usually directed against the
NC1 domain of type IV collagen found
primarily in the renal and respiratory
tracts.10 Acute renal failure is the most
common presenting illness and roughly
half of affected patients have clinical
evidence of alveolar haemorrhage with
cough, progressive dyspnoea or overt
haemoptysis.11 Concurrent systemic vasculitis is suggested clinically by the

presence of constitutional symptoms
such as fevers, weight loss and malaise,
and by the presence of positive ANCA,
usually M
 PO-ANCA, which is found in
up to a third of patients with anti-GBM
vasculitis.12
Demonstration of serum, pulmonary
or renal anti-GBM antibodies using direct
enzyme-linked immunoassay (ELISA)
and confirmed with western blot is
diagnostic. Renal biopsy should always
be performed if possible as it is more
accurate and guides treatment. Immuno
fluorescence of biopsy specimens reveals
the pathognomonic linear immuno
globulin G (IgG) deposition in the basement membrane of glomerular capillaries
(Figure 213).14

Patients are managed initially with a
combination of corticosteroids and
either cyclophosphamide, rituximab or
mycophenolate mofetil for three to six
months, as well as up to six weeks of
intensive plasmapheresis to remove
circulating a nti-GBM antibodies.15 AntiGBM antibody levels, together with
clinical response, guides the need for
repeat plasmapheresis. Maintenance
therapy with low-dose prednisolone with
or without a second agent such as azathioprine or mycophenolate mofetil is
recommended for nine months.
Immunoglobulin A vasculitis
Immunoglobulin A (IgA) vasculitis, also
known as Henoch-Schönlein purpura
(HSP), is a small-vessel vasculitis more
common in Asian populations that
predominantly affects children under
15 years old.16 The major clinical mani
festations include palpable purpura
primarily on the buttocks and lower limbs
(Figure 3), non-deforming migratory
oligoarthralgia of the lower limb large
joints, colicky abdominal pain sometimes with bleeding and renal disease.

Figure 2. Linear immunoglobulin G deposition
in the basement membrane of glomerular
capillaries pathognomonic of anti-glomerular
basement membrane vasculitis.
Reproduced from Silva N, Oliveira L, Frutuoso M,
Morgado T. Anti-glomerular basement membrane disease:
a case report of an uncommon presentation. J Clini
Nephrol. 2019; 3: 61-65 under the terms of the Creative
Commons Attribution License.

Haematuria and an active urinary sediment are typically found and renal dysfunction is typically self-limited.17 Markers
of poor prognosis include prolonged
abnormalities of the urinary sediment,
heavy proteinuria, hypertension and
impairment of renal function with an
elevated serum creatinine level. Serum
IgA levels are elevated in approximately
half of cases and are a ssociated with renal
dysfunction.18 IgA deposition on immuno
fluorescence of skin or renal biopsy
specimens is usually required to make the
diagnosis in adult patients.

Figure 3. Classic palpable purpura of
immunoglobulin A vasculitis.
Reproduced with permission from the Mayo Foundation
for Medical Education and Research. © Mayo Foundation
for Medical Education and Research. All rights reserved.
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TABLE 2. COMMON SITES OF EXTRACUTANEOUS MANIFESTATIONS IN PATIENTS
WITH HYPOCOMPLEMENTAEMIC URTICARIAL VASCULITIS
Site

Manifestations

Joints

• Migratory polyarthritis and arthralgias sometimes accompanied by
Jaccoud’s deforming nonerosive arthropathy

Eyes

• Episcleritis
• Uveitis
• Conjunctivitis

Lungs

• Cough
• Hemoptysis
• Chronic obstructive pulmonary disease (COPD)

Gastrointestinal
tract

•
•
•
•

Kidneys

• Mild nonprogressive renal disease with haematuria and light
proteinuria

Abdominal pain
Nnausea
Vomiting
Diarrhoea without bleeding

Hydration, rest and simple analgesia
with NSAIDs are first line management
strategies for symptomatic control. For
patients with heavy proteinuria, therapy
with an ACE inhibitor or angiotensinreceptor blocker (ARB) is recommended.
Low-dose prednisolone may be considered in more severe or prolonged disease.
Monitoring renal function and urinary
sediment is a mainstay of management
throughout.19 Patients with severe or prolonged disease (greater than six months)
should undergo renal biopsy to demonstrate active inflammation and, if present, immunosuppressive therapy with
cyclophosphamide or mycophenolate is
recommended.20
Hypocomplementaemic urticarial
vasculitis
Hypocomplementaemic urticarial vasculitis (HUV) describes a wide range of
clinical syndromes characterised by the
presence of urticaria and dermatological
biopsy evidence of leukocytoclastic
vasculitis. Immune complex deposition
in vessel walls activates complement
proteins, which stimulates mast cell
degranulation and clinical urticaria.21
Complement protein levels are reduced
in more severe or widespread disease.
26 MedicineToday

The clinical course is prolonged, usually
occurring over months to years. Roughly
half of patients with HUV experience
constitutional symptoms and the most
common sites of extracutaneous manifestations are summarised in Table 2.
A skin biopsy should be undertaken
early to guide further investigation and
treatment. Should the diagnosis of
HUV be confirmed on biopsy, inflamma
tory markers, renal function, urinalysis,
hepatitis serology, ANCA and an auto
antibody panel, complement protein levels
with C1q precipitin (anti-C1q antibody),
immunofixation electrophoresis and
cryoglobulin levels should be obtained.
Most disease is mild and responds
well to supportive treatment with anti
histamines and NSAIDs. Corticosteroids
with the addition of dapsone, colchicine
or hydroxychloroquine may be indicated
in cases where symptomatic treatment is
inadequate. Severe disease, defined by the
presence of end-organ dysfunction, typically requires longer term immunosuppressive therapy with mycophenolate
mofetil or another steroid-sparing agent.24
Cryoglobulinaemic vasculitis
Cryoglobulinaemic vasculitis is a manifestation of cryoglobulinaemia, a

heterogeneous group of diseases caused
by the precipitation of blood proteins,
chiefly immunoglobulin and complement. The systemic inflammation resulting from the precipitation of these
proteins primarily affects medium and
small vessels. Cutaneous manifestations
are nearly universal.25 Arthralgias are
also common with a proclivity for metacarpophalangeal and proximal phalangeal joints, knees and ankles.26 Peripheral
neuropathy and renal involvement,
primarily in the form of membranoproliferative glomerulonephritis, a sub
clinical small airways disease, also affects
a sizable minority of patients with
cryoglobulinaemia.
Investigations are aimed at diagnosis
of underlying connective tissue disease
(SLE, Sjögren’s), monoclonal haematolo
gical disorder (multiple myeloma,
Waldenström’s macroglobulinaemia) or
chronic viral infections (HCV or HBV).
C4 complement levels are almost always
reduced in cryoglobulinaemic vasculitis.27 Detection of cryoglobulins is a precise and complex laboratory process
which must be executed correctly to avoid
false positives. A cryocrit greater than
0.5% or cryoglobulin concentration
greater than 50 mcg/mL is considered
clinically signif icant.28 Management of
cryoglobulinaemic vasculitis consists of
identification and treatment of the
underlying condition.
Leukocytoclastic vasculitis
Leukocytoclastic vasculitis (LCV), also
referred to as hypersensitivity vasculitis,
is the commonest vasculitis encountered
in clinical practice. It is a skin-isolated
vasculitis of the small vessels and may be
idiopathic or secondary. The term ‘leuko
cytoclastic’ refers to the death and breakdown of neutrophils after degranulation.
LCV presents most commonly with palpable purpura of the lower limbs without
haematuria or other evidence of major
visceral involvement. It is important to
exclude systemic vasculitis or infection
in cases of suspected LCV. Diagnosis is
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made with a combination of clinical and
skin biopsy findings and is described
by the American College of Rheumatology criteria.29 These criteria are met if at
least three out of five of the following are
observed:
1. age over 16 years old
2. temporal relationship to new or
changed medication
3. palpable purpura
4. maculopapular rash
5. perivascular neutrophils and
fibrinoid necrosis seen on skin
biopsy.
Skin biopsy occasionally reveals eosinophils, which strongly suggest a pharmacological aetiology. The most common medications implicated are sulfonamides such as frusemide and thiazide
diuretics, penicillin and cephalosporin
antibiotics, allopurinol, and phenytoin.30
In most cases, management is supportive
in a ddition to cessation of the offending
agent if known and possible.

Investigations
Although clinical features of systemic
vasculitis are usually nonspecific, symptoms such as haemoptysis, haematuria,
renal failure, asthma and jaw claudication
can help sharpen the differential. Likewise, features of systemic disease such as
SLE, rheumatoid arthritis, HIV or infective endocarditis can be helpful in directing investigations and therapy. Initial
laboratory tests should include inflammatory markers (erythrocyte sedimentation rate and C-reactive protein), as
well as measures of organ function such
as serum creatinine level and liver function tests. Serology for HBV, HCV, HIV
and cryoglobulins is typically undertaken as well. Urine specimens should
be sent for routine analysis, microscopy
and examination of the sediment. Microbiological cultures, serology and imaging
guided by symptoms should be obtained
to exclude simple infections. A careful
medication and exposure history should
be undertaken in consideration of a reactive process.

In the case of small vessel disease and/
or vasculitis occurring in the context of
another suspected systemic inflammatory
condition, autoimmune serology should
be obtained, including ANCA with protease 3 and MPO staining, antinuclear
antibody, rheumatoid factor and complement protein levels. More specific serology should be performed to confirm
diagnoses suggested by the initial screen,
including anti-double stranded deoxyribonucleic acid antibodies, extractable
nuclear antigens and anti-cyclic citrullinated peptide antibodies. In the presence
of haemoptysis, plain chest radiography
and high-resolution CT scan of the chest
should be undertaken to guide subsequent
therapy. In large vessel vasculitis and
suspected polyarteritis nodosa, CT or
magnetic resonance angiography is
usually undertaken to visualise sites of
involvement and confirm the presence of
complications such as aneurysms, dissections or occlusions. Tissue sampling is
often integral to diagnosis: temporal arteries in suspected GCA, renal biopsy in the
context of renal dysfunction or an active
urinary sediment, and skin biopsy with
dermatological manifestations such as
Henoch-Schönlein purpura or HIV.

Therapy and outcomes
Management of primary systemic vasculitides involves the induction and
maintenance of remission, as well as
prevention and management of complications and end-organ dysfunction
resulting from vascular injury. Corticosteroids form the backbone of induction
regimens, often in high doses compared
with systemic r heumatologic conditions.
In patients requiring prolonged maintenance therapy, steroid-sparing agents
including thiopurines, mycophenolate
and calcineurin inhibitors are preferred
to long-term steroids. In secondary disease, management focuses on the underlying condition (i.e. cryoglobulinaemic
vasculitis in HCV).
It is important to adhere to vaccination
and infection prophylaxis guidelines,

especially when combination immunosuppressive or high-dose corticosteroid
therapy is used. Furthermore, patients
with high burdens of corticosteroid
therapy should be screened for systemic
complications such as diabetes mellitus,
hypertension, obesity and osteoporosis,
and managed appropriately.
Diagnosis, management and monitoring take place primarily in the community,
thus the general practitioner is integral to
the management of most patients with
vasculitis. Vasculitis accompanying systemic disorders such as rheumatoid arthritis or viral hepatitis often merit specialist
involvement and regular follow up. Early
and urgent referral to a vascular or other
relevant physician specialist such as an
immunologist or a rheumatologist should
be obtained for patients who have evidence
of progressive disease and in those with
end-organ dysfunction. In patients with
haemoptysis, severe renal impairment or
suspected GCA with visual compromise,
immediate hospitalisation is indicated.

Conclusion
The vasculitides are a diverse group of
conditions whose specific manifestations
generally depend on the size of vessels
involved. Important complications of
these varied diseases such as visual compromise, renal dysfunction, pulmonary
haemorrhage and vascular aneurysms
must be considered. Specialist involvement is crucial and should be obtained
urgently if such complications are present.
In patients receiving long-term corticosteroid or immunosuppressive therapy,
dedicated screening for chronic iatrogenic
complications such as diabetes mellitus,
osteoporosis, hypertension, obesity,
opportunistic infections and secondary
malignancies is crucial to achieve optimal
health outcomes.   MT
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